Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
Clinical trial NCT01350804 · COMPLETED
Trial details
- NCT number
- NCT01350804
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-09-01
- Primary completion
- 2015-02-01
- Enrollment
- 551
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.